Savara Inc. (NASDAQ:SVRA) Stock Has Average Target Price of $10.25 According to Analysts

Key Points

• Analysts maintain a Moderate Buy consensus on Savara, with seven buys, one strong buy and one sell among nine analysts. The average 12-month price target is $10.25, including JPMorgan’s $12 target and RBC’s $10 target.
• Institutional investors hold 87.93% of Savara’s shares, with BlackRock, Polar Capital, Nantahala Capital and others recently establishing or expanding positions.
• SVRA opened at $4.84, below its 50-day and 200-day moving averages, while Savara’s latest quarterly loss of $0.16 per share missed the $0.14 consensus estimate. The clinical-stage biotech is developing inhaled molgramostim for autoimmune pulmonary alveolar proteinosis.

Savara Inc. (NASDAQ:SVRA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $10.25.

SVRA has been the subject of several recent analyst reports. Wall Street Zen downgraded shares of Savara from a "hold" rating to a "sell" rating in a research note on Sunday, October 4th. JPMorgan Chase & Co. initiated coverage on shares of Savara in a research report on Wednesday, October 7th. They set an "overweight" rating and a $12.00 price target on the stock. Royal Bank Of Canada set a $10.00 price target on shares of Savara in a report on Wednesday, October 7th. Weiss Ratings reissued a "sell (d-)" rating on shares of Savara in a report on Friday, July 17th. Finally, Citigroup restated a "market outperform" rating on shares of Savara in a research report on Wednesday, October 7th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SVRA. BlackRock Inc. bought a new stake in shares of Savara in the second quarter worth about $76,966,000. Polar Capital Holdings Plc acquired a new stake in shares of Savara during the fourth quarter worth about $50,086,000. Nantahala Capital Management LLC acquired a new stake in shares of Savara during the second quarter worth about $42,977,150. Spruce Street Capital LP bought a new position in shares of Savara during the 2nd quarter valued at about $21,267,868. Finally, Pictet Asset Management Holding SA bought a new position in shares of Savara during the 1st quarter valued at about $12,424,000. 87.93% of the stock is currently owned by institutional investors.

Savara Stock Performance

Shares of SVRA stock opened at $4.84 on Tuesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.13 and a quick ratio of 10.13. The stock has a market cap of $994.43 million, a PE ratio of -8.34 and a beta of 0.20. The stock has a 50-day moving average of $5.31 and a 200-day moving average of $5.41. Savara has a one year low of $3.35 and a one year high of $7.01.

Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). As a group, sell-side analysts expect that Savara will post -0.66 earnings per share for the current year.

Savara Company Profile

Savara Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled formulation of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which surfactant accumulates in the lungs and impairs breathing.

Savara has conducted clinical development activities in the United States and internationally, including Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.